Nexletol (Bempedoic Acid) Patent Expiration, LOE Window & CMS Spending
Nexletol (Bempedoic Acid) by Esperion Therapeutics: FDA Orange Book core substance LOE 2040-06-19, 0 AB generics, $76.1M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Esperion Therapeutics |
| FDA Application & Pathway | N211616 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2040-06-19 |
| Last Listed Patent or Exclusivity Date | 2040-06-19 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $76.1M |
| 2024 Medicare Part D Spend | $70.9M |
| 2024 Medicaid Spend | $5.2M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 20.0% 2-yr change) |